rexresearch.com
Cassandra QUAVE, et al.
Herbs vs MRSA
http://preventdisease.com/news/17/021317_Peppertree-Disarms-Most-Dangerous-Bacteria.shtml
Prevent Disease
Common weed found to disarm
MRSA superbug
by Karen Foster
Superbugs are without a doubt a major threat affecting all health
care systems. Methicillin-resistant Staphylococcus aureus (MRSA)
infection is caused by a type of staph bacteria that's become
resistant to many of the antibiotics used to treat ordinary staph
infections. Despite attempts by new antibiotics to neutralize the
effects of MRSA, none have succeeded. But nature did.
The red berries of the Brazilian peppertree -- a weedy, invasive
species common in Florida -- contain an extract with the power to
disarm dangerous antibiotic-resistant staph bacteria, scientists
at Emory University have discovered.
The journal Scientific Reports is publishing the finding, made in
the lab of Cassandra Quave, an assistant professor in Emory's
Center for the Study of Human Health and in the School of
Medicine's Department of Dermatology.
"Traditional healers in the Amazon have used the Brazilian
peppertree for hundreds of years to treat infections of the skin
and soft tissues," Quave says. "We pulled apart the chemical
ingredients of the berries and systematically tested them against
disease-causing bacteria to uncover a medicinal mechanism of this
plant."
The researchers showed that a refined, flavone-rich composition
extracted from the berries inhibits formation of skin lesions in
mice infected with MRSA. The compound works not by killing the
MRSA bacteria, but by repressing a gene that allows the bacteria
cells to communicate with one another. Blocking that communication
prevents the cells from taking collective action, a mechanism
known as quorum quenching.
"It essentially disarms the MRSA bacteria, preventing it from
excreting the toxins it uses as weapons to damage tissues," Quave
says. "The body's normal immune system then stands a better chance
of healing a wound."
While infections are becoming increasingly difficult to beat, no
new class of antibiotic has been discovered since 1987. In
contrast, a new infection emerges on an almost yearly basis.
The discovery may hold potential for new ways to treat and prevent
antibiotic-resistant infections, a growing international problem.
Antibiotic-resistant infections annually cause at least two
million illnesses and 23,000 deaths in the United States,
according to the Centers for Disease Control and Prevention. The
United Nations last year called antibiotic-resistant infections a
"fundamental threat" to global health and safety, citing estimates
that they cause at least 700,000 deaths each year worldwide, with
the potential to grow to 10 million deaths annually by 2050.
Bacteria are rife in conventionally grown US meat including
antibiotic-resistant bacteria also known as superbugs. Almost half
of beef, chicken, pork and turkey in samples tested from US
grocery stores contained staph bacteria reported the Los Angeles
Times in 2011 including the resistant MRSA staph bacterium
(methicillin-resistant S. aureus). Pork tested by Consumer Reports
in 2013 also contained MRSA and four other kinds of resistant
bacteria.
Blasting deadly bacteria with drugs designed to kill them is
helping to fuel the problem of antibiotic resistance. Some of the
stronger bacteria may survive these drug onslaughts and
proliferate, passing on their genes to offspring and leading to
the evolution of deadly "super bugs."
In contrast, the Brazilian peppertree extract works by simply
disrupting the signaling of MRSA bacteria without killing it. The
researchers also found that the extract does not harm the skin
tissues of mice, or the normal, healthy bacteria found on skin.
"In some cases, you need to go in heavily with antibiotics to
treat a patient," Quave says. "But instead of always setting a
bomb off to kill an infection, there are situations where using an
anti-virulence method may be just as effective, while also helping
to restore balance to the health of a patient. More research is
needed to better understand how we can best leverage
anti-virulence therapeutics to improve patient outcomes."
Quave, a leader in the field of medical ethnobotany and a member
of the Emory Antibiotic Resistance Center, studies how indigenous
people incorporate plants in healing practices to uncover
promising candidates for new drugs.
The Brazilian peppertree (Schinus terebinthifolia) is native to
South America but thrives in subtropical climates. It is abundant
in much of Florida, and has also crept into southern areas of
Alabama, Georgia, Texas and California. Sometimes called the
Florida holly or broad leaf peppertree, the woody plant forms
dense thickets that crowd out native species.
"The Brazilian peppertree is not some exotic and rare plant found
only on a remote mountaintop somewhere," Quave says. "It's a weed,
and the bane of many a landowner in Florida."
From an ecological standpoint, it makes sense that weeds would
have interesting chemistry, Quave adds. "Persistent, weedy plants
tend to have a chemical advantage in their ecosystems, which help
may protect them from diseases so they can more easily spread in a
new environment."
https://en.wikipedia.org/wiki/Schinus_terebinthifolius
Schinus terebinthifolius
Starr 041018-0009 Schinus terebinthifolius.jpg
Scientific classification
Kingdom: Plantae, Angiosperms, Eudicots, Rosids, Order:
Sapindales; Family: Anacardiaceae; Genus: Schinus ; Species: S.
terebinthifolia
Binomial name : Schinus terebinthifolia Raddi, 1820[1]
Schinus terebinthifolia is a species of flowering plant in the
cashew family, Anacardiaceae, that is native to subtropical and
tropical South America (southeastern Brazil, northern Argentina,
and Paraguay). It is found in these states of Brazil: Alagoas,
Bahia, Espírito Santo, Mato Grosso do Sul, Minas Gerais,
Pernambuco, Paraná, Rio de Janeiro, Rio Grande do Norte, Rio
Grande do Sul, Santa Catarina, São Paulo, and Sergipe. Common
names include Brazilian peppertree,[2] aroeira, rose pepper,
broadleaved pepper tree,[3] wilelaiki (or wililaiki),[4] and
Christmasberry.[5]
Description
Brazilian peppertree is a sprawling shrub or small tree, with a
shallow root system, reaching a height of 7–10 m. The branches can
be upright, reclining, or nearly vine-like, all on the same plant.
Its plastic morphology allows it to thrive in all kinds of
ecosystems: from dunes to swamps, where it grows as a semiaquatic
plant.[6] The leaves are alternate, 10–22 cm long, pinnately
compound with (3–) 5–15 leaflets; the leaflets are roughly oval
(lanceolate to elliptical), 3–6 cm long and 2–3.5 cm broad, and
have finely toothed margins, an acute to rounded apex and
yellowish veins. The leaf rachis between the leaflets is usually
(but not invariably) slightly winged. The plant is dioecious, with
small white flowers borne profusely in axillary clusters. The
fruit is a drupe 4–5 mm diameter, carried in dense clusters of
hundreds.
The two varieties are:
S. terebinthifolius var. acutifolius, leaves to 22 cm, with 7–15
leaflets, fruit pink
S. terebinthifolius var. terebinthifolius, leaves to 17 cm, with
5–13 leaflets, fruit red
Cultivation and uses
Brazilian pepper is widely grown as an ornamental plant in
frost-free regions of South America for its foliage and fruit. It
is considered as a melliferous flower[6] and is the main source of
food for the bee Tetragonisca angustula, which is an important
honey producer.[7]
Although it is not a true pepper (Piper), its dried drupes are
often sold as pink peppercorns, as are the fruits from the related
species Schinus molle (Peruvian peppertree). The seeds can be used
as a spice, adding a pepper-like taste to food. They are usually
sold in a dry state and have a bright pink color. They are less
often sold pickled in brine, where they have a dull, almost green
hue.
In the United States, it has been introduced to California, Texas,
Hawaii, Arizona, Nevada, Louisiana,[8] and Florida. Planted
originally as an ornamental outside of its native range, Brazilian
pepper has become widespread and is considered an invasive species
in many subtropical regions with moderate to high rainfall,
including parts or all of Australia, the Bahamas, Bermuda,
southern China, Cuba, Fiji, French Polynesia, Guam, Hawaii, Malta,
the Marshall Islands, Mauritius, New Caledonia, New Zealand,
Norfolk Island, Puerto Rico, Réunion, South Africa, and the United
States. In drier areas, such as Israel and southern California, it
is also grown, but has not generally proved invasive. In
California, it is considered invasive in coastal regions by the
California Invasive Plant Council (www.cal-ipc.org.)
Brazilian pepper is hard to control because it produces basal
shoots if the trunk is cut. Trees also produce abundant seeds that
are dispersed by birds and ants. This same hardiness makes the
tree highly useful for reforestation in its native environment,
but enables it to become invasive outside of its natural range.[6]
Toxicity
Like many other species in the family Anacardiaceae, Brazilian
pepper has an aromatic sap that can cause skin reactions (similar
to poison ivy burns) in some sensitive people – although the
reaction is usually weaker than that induced by touch of the
closely related Lithraea molleoides, known in Brazil as "wild"
aroeira (aroeira brava). Conversely, Schinus terebinthifolius is
commonly known as "tame" aroeira (aroeira mansa).
In a paper on triterpenes, the ingested fruits are noted to have a
“paralyzing effect” on birds.[9] The narcotic and toxic effects on
birds and other wildlife has also been noted by others, e.g.,
Bureau of Aquatic Plant Management. The AMA Handbook of Poisonous
and Injurious Plants reports that the triterpenes found in the
fruits can result in irritation of the throat, gastroenteritis,
diarrhea, and vomiting in man.[10] Like most other members of the
Anacardiaceae, Brazilian pepper contains active alkenyl phenols,
e.g., urushiol, cardol, which can cause contact dermatitis and
inflammation in sensitive individuals.[11][12] Contact with the
“sap” from a cut or bruised tree can result in rash, lesions,
oozing sores, severe itching,reddening and swelling (especially of
the eyes), and welts.[13]
The burning of plant matter releases many airborne irritants, so
is not an effective means of control. It is said to have a
"mace-like" effect upon nearby people and is highly advised
against.
History
"Florida holly" was introduced to Florida by at latest 1891,
probably earlier,[14] where it has spread rapidly since about
1940,[15] replacing native plants, like mangroves, with thousands
of acres occupied. It is especially adept at colonizing disturbed
sites and can grow in both wet and dry conditions. Its growth
habit allows it to climb over understory trees and invade mature
canopies, forming thickets that choke out most other plants.
Legal status
The species, including the seed, is legally prohibited from sale,
transport, or planting in Florida, according to the Florida
Department of Agriculture and Consumer Services Noxious Weed
List.[16] It is classified as a Category I pest by The Florida
Exotic Pest Plant Council (FL EPPC).[17] To keep the plant from
spreading into native plant communities and displacing them, local
regulations and environmental guidelines require eradication of
Brazilian pepper wherever possible. The plant and all parts are
also illegal for sale or transfer in Texas.[18] As one of the two
species sold as pink peppercorn, the other being Schinus molle, it
lacks generally recognized as safe (GRAS) status with the FDA.[19]
It is a declared weed in several states of Australia.[20][21][22]
In South Africa, it is classified as a category 1 invader in
KwaZulu-Natal province, where any plants are to be removed and
destroyed, and a category 3 invader in all other provinces,
meaning it may no longer be planted.[23]
Control
Two herbicides are approved for use in the United States to
exterminate Brazilian pepper: Triclopyr, using the basal bark
method; and glyphosate. Picloram can be used if the stump has been
freshly cut, but this is not the preferred nor most effective
means of eradication.
Medicinal uses
Peppertree is the subject of extensive folk medicinal lore where
it is indigenous. Virtually all parts of this tropical tree,
including its leaves, bark, fruit, seeds, resin, and oleoresin (or
balsam) have been used medicinally by indigenous peoples
throughout the tropics. The plant has a very long history of use
and appears in ancient religious artifacts and on idols among some
of the ancient Chilean Amerindians.[citation needed]
Throughout South and Central America, Brazilian peppertree is
reported to be an astringent, antibacterial, diuretic, digestive
stimulant, tonic, antiviral, and wound healer. In Peru, the sap is
used as a mild laxative and a diuretic, and the entire plant is
used externally for fractures and as a topical antiseptic. The
oleoresin is used externally as a wound healer, to stop bleeding,
and for toothaches, and it is taken internally for rheumatism and
as a purgative. In South Africa, a leaf tea is used to treat
colds, and a leaf decoction is inhaled for colds, hypertension,
depression, and irregular heart beat. In the Brazilian Amazon, a
bark tea is used as a laxative, and a bark-and-leaf tea is used as
a stimulant and antidepressant. In Argentina, a decoction is made
with the dried leaves and is taken for menstrual disorders and is
also used for respiratory and urinary tract infections and
disorders.[citation needed]
Brazilian peppertree is still employed in herbal medicine today in
many countries. It is used for many conditions in the tropics,
including menstrual disorders, bronchitis, gingivitis, gonorrhea,
gout, eye infections, rheumatism, sores, swellings, tuberculosis,
ulcers, urethritis, urogenital disorders, venereal diseases,
warts, and wounds. In Brazilian herbal medicine today, the dried
bark and/or leaves are employed for heart problems (hypertension
and irregular heart beat), infections of all sorts, menstrual
disorders with excessive bleeding, tumors, and general
inflammation. A liquid extract or tincture prepared with the bark
is used internally as a stimulant, tonic, and astringent, and
externally for rheumatism, gout, and syphilis. [24]
Recently, the fruit of the plant has been studied and shows
promise as a treatment for MRSA. A chemical in the berry appears
to stop bacteria from producing a toxin which breaks down tissue.
It also appears to suppress the way the bacteria communicate. [25]
References
"Schinus terebinthifolia Raddi". Germplasm Resources Information
Network. United States Department of Agriculture. 2009-03-30.
Retrieved 2009-12-30.
"Schinus terebinthifolius". Natural Resources Conservation Service
PLANTS Database. USDA. Retrieved 6 November 2015.
"Broadleaved pepper tree (Schinus terebinthifolius)".
www.daf.qld.gov.au. Retrieved 2015-07-19.
"Christmas-berry" (PDF). Retrieved 2016-12-04.
(Portuguese) Schinus terebinthifolius at Instituto de Pesquisas e
Estudos Florestais
Paulo Backes & Bruno Irgang, Mata Atlântica: as árvores e a
paisagem, Porto Alegre, Paisagem do Sul, 2004, page 102
Braga, JA; Sales, EO; Soares Neto, J; Conde, MM; Barth, OM; Maria,
CL (December 2012). "Floral sources to Tetragonisca angustula
(Hymenoptera: Apidae) and their pollen morphology in a
Southeastern Brazilian Atlantic Forest.". Revista de biologia
tropical. 60 (4): 1491–501. doi:10.15517/rbt.v60i4.2067. PMID
23342504.
"Schinus terebinthifolius; Element stewardship abstract" (PDF).
Campello, J.P. and A.J. Marsaioli. 1974. Triterpenes of
Schinusterebinthifolius. Phytochem. 13: 659-660
Lampe, K.F. and M.A. McCann. 1985. AMA Handbook of Poisonous and
Injurious Plants.American Medical Association, Chicago.
Lampe, K.F. and R. Fagerstrom. 1968. Plant Toxicity and
Dermatitis. Williams & Wilkins Co.,Baltimore
Tomlinson, P.B. 1980. The Biology of Trees Native to Tropical
Florida. Harvard University Printing Office, Allston.
Morton, J.F. 1978. Brazilian pepper - Its impact on people,
animals and the environment. Econ. Bot.32: 353-359.
Gogue, G. J.; Hurst, C. J.; Bancroft, L. (1974). "Growth
inhibition by Schinus terebinthifolius". HortScience. 9 (3): 301.
Ewel, J. J. 1986. Invasibility: Lessons from south Florida. in H.
A. Mooney and J. A. Drake, eds. Ecology of biological invasions of
North America and Hawaii, pp. 214–230. Springer-Verlag, New York.
(F.A.C. 5B-57.007)
http://www.doacs.state.fl.us/pi/enpp/botany/noxweed.html Florida
Department of Agriculture & Consumer Services
Florida Florida Exotic Pest Plant Council
Texas Invasives
Singh, Ram J.; Lebeda, Ales; Tucker, Arthur O. (2011). "2.
Medicinal Plants—Nature's Pharmacy". In Singh, Ram J. Genetic
Resources, Chromosome
Engineering, and Crop Improvement: Medicinal Plants. 6. CRC Press
(published 15 September 2011). p. 17. ISBN 978-1420073843.
Broadleaved pepper tree Schinus terebinthifolius Declared Class 3
(PDF)
Broad-leaf pepper tree
Swan Weeds — List of Weeds
"Invasive Alien Plants - CARA List". South African Nursery
Association.
"Tropical Plant Database".
https://www.washingtonpost.com/news/to-your-health/wp/2017/02/10/common-weed-could-help-fight-deadly-superbug-study-finds/#pt0-293591
https://www.nytimes.com/2016/09/18/magazine/could-ancient-remedies-hold-the-answer-to-the-looming-antibiotics-crisis.html?_r=0
Could Ancient Remedies Hold the Answer to
the Looming Antibiotics Crisis?
One researcher thinks the drugs of the future might come from
the past: botanical treatments long overlooked by Western
medicine.
By FERRIS JABR
...Recently, Quave and her research team have discovered that an
extract of Brazilian peppertree berries — an invasive species
common in many warmer parts of the United States — prevents MRSA
from forming skin lesions in mice and shrinks biofilms formed by
the bacteria. “I really believe these kind of inhibitors are a
major part of the solution to antibiotic resistance,” Quave says.
“We can shut down bacteria’s most dangerous machinery without
killing them.” She envisions using such drugs as prophylactics in
surgeries with a high infection risk, or in combination with other
antimicrobials if a serious infection is already established...
https://www.researchgate.net/profile/Cassandra_Quave/publications
https://www.researchgate.net/publication/313592977_Virulence_Inhibitors_from_Brazilian_Peppertree_Block_Quorum_Sensing_and_Abate_Dermonecrosis_in_Skin_Infection_Models
Scientific Reports 7:42275 (February 2017)
DOI: 10.1038/srep42275
Virulence Inhibitors from Brazilian
Peppertree Block Quorum Sensing and Abate Dermonecrosis in
Skin Infection Models
Amelia Muhs, et al.
https://www.sciencedaily.com/releases/2015/08/150821164150.htm
Chestnut leaves yield extract that disarms
deadly staph bacteria
Extract shuts down staph without boosting its drug
resistance
Leaves of the European chestnut tree contain ingredients with the
power to disarm dangerous staph bacteria without boosting its drug
resistance, scientists have found.
PLOS ONE is publishing the study of a chestnut leaf extract, rich
in ursene and oleanene derivatives, that blocks Staphlococcus
aureus virulence and pathogenesis without detectable resistance.
The use of chestnut leaves in traditional folk remedies inspired
the research, led by Cassandra Quave, an ethnobotanist at Emory
University.
"We've identified a family of compounds from this plant that have
an interesting medicinal mechanism," Quave says. "Rather than
killing staph, this botanical extract works by taking away staph's
weapons, essentially shutting off the ability of the bacteria to
create toxins that cause tissue damage. In other words, it takes
the teeth out of the bacteria's bite."
The discovery holds potential for new ways to both treat and
prevent infections of methicillin-resistant S. aureus, or MRSA,
without fueling the growing problem of drug-resistant pathogens.
Antibiotic-resistant bacteria annually cause at least two million
illnesses and 23,000 deaths in the United States, according to the
Centers for Disease Control and Prevention. MRSA infections lead
to everything from mild skin irritations to fatalities. Evolving
strains of this "super bug" bacterium pose threats to both
hospital patients with compromised immune systems and young,
healthy athletes and others who are in close physical contact.
"We've demonstrated in the lab that our extract disarms even the
hyper-virulent MRSA strains capable of causing serious infections
in healthy athletes," Quave says. "At the same time, the extract
doesn't disturb the normal, healthy bacteria on human skin. It's
all about restoring balance."
Quave, who researches the interactions of people and plants -- a
specialty known as ethnobotany -- is on the faculty of Emory's
Center for the Study of Human Health and Emory School of
Medicine's Department of Dermatology. She became interested in
ethnobotany as an undergraduate at Emory.
For years, she and her colleagues have researched the traditional
remedies of rural people in Southern Italy and other parts of the
Mediterranean. "I felt strongly that people who dismissed
traditional healing plants as medicine because the plants don't
kill a pathogen were not asking the right questions," she says.
"What if these plants play some other role in fighting a disease?"
Hundreds of field interviews guided her to the European chestnut
tree, Castanea sativa. "Local people and healers repeatedly told
us how they would make a tea from the leaves of the chestnut tree
and wash their skin with it to treat skin infections and
inflammations," Quave says.
For the current study, Quave teamed up with Alexander Horswill, a
microbiologist at the University of Iowa whose lab focuses on
creating tools for use in drug discovery, such as glow-in-the-dark
staph strains.
The researchers steeped chestnut leaves in solvents to extract
their chemical ingredients. "You separate the complex mixture of
chemicals found in the extract into smaller batches with fewer
chemical ingredients, test the results, and keep honing in on the
ingredients that are the most active," Quave explains. "It's a
methodical process and takes a lot of hours at the bench. Emory
undergraduates did much of the work to gain experience in chemical
separation techniques."
The work produced an extract of 94 chemicals, of which ursene and
oleanene based compounds are the most active.
Tests showed that this extract inhibits the ability of staph
bacteria to communicate with one another, a process known as
quorum sensing. MRSA uses this quorum-sensing signaling system to
manufacture toxins and ramp up its virulence.
"We were able to trace out the pathways in the lab, showing how
our botanical extract blocks quorum sensing and turns off toxin
production entirely," Quave says. "Many pharmaceutical companies
are working on the development of monoclonal antibodies that
target just one toxin. This is more exciting because we've shown
that with this extract, we can turn off an entire cascade
responsible for producing a variety of different toxins."
A single dose of the extract, at 50 micrograms, cleared up MRSA
skin lesions in lab mice, stopping tissue damage and red blood
cell damage. The extract does not lose activity, or become
resistant, even after two weeks of repeated exposure. And tests on
human skin cells in a lab dish showed that the botanical extract
does not harm the skin cells, or the normal skin micro-flora.
The Emory Office of Technology Transfer has filed a patent for the
discovery of the unique properties of the botanical extract. The
researchers are doing further testing on individual components of
the extract to determine if they work best in combination or
alone.
"We now have a mixture that works," Quave says. "Our goal is to
further refine it into a simpler compound that would be eligible
for FDA consideration as a therapeutic agent."
Potential uses include a preventative spray for football pads or
other athletic equipment; preventative coatings for medical
devices and products such as tampons that offer favorable
environments for the growth of MRSA; and as a treatment for MRSA
infections, perhaps in combination with antibiotics.
"It's easy to dismiss traditional remedies as old wives' tales,
just because they don't attack and kill pathogens," Quave says.
"But there are many more ways to help cure infections, and we need
to focus on them in the era of drug-resistant bacteria."
http://grantome.com/grant/NIH/R01-AT007052-04
Mechanistic Studies on Staphylococcal
Quorum Quenching Natural Products
Quave, Cassandra Leah
Emory University, Atlanta, GA, United State
Abstract
Staphylococcus aureus is a highly problematic pathogen. Rates of
infection in both the community and healthcare setting are on the
rise, and coupled with its highly antibiotic-resistant nature,
this makes S. aureus a top public health concern. In fact,
invasive methicillin-resistant S. aureus (MRSA) is responsible for
more deaths in the USA than AIDS. Nevertheless, the number of new
antibiotic leads in the pipeline is diminishing, and many
scientists have put out a call for the discovery and development
of a new class of drugs which could mediate microbial
pathogenicity rather than growth and survival. The staphylococcal
quorum-sensing pathway, controlled by the accessory gene regulator
(agr) system, is a potential target for such anti-pathogenic drug
discovery efforts, as it serves as a global regulator of
staphylococcal virulence. Following extensive studies on the
complementary and alternative medical (CAM) practices of southern
Italians in the treatment of skin and soft tissue infection, over
100 plant samples were identified, collected, extracted, and
examined for their anti-staphylococcal potential. Among the tests
included was a screen for the inhibition of??-hemolysin, a
translational protein product of RNAIII, whose production is
regulated through the agr quorum-sensing pathway. Extract 134,
which is derived from a popular tree with edible fruits and
medicinal leaves and bark, was found to exhibit a strong
dose-dependent inhibition of ?-hemolysin at sub-inhibitory
concentrations for growth. The dose-dependent quorum-quenching
effects of Extract 134 were confirmed through the use of
fluorescent genetic reporters for agr (types I-IV). This activity
is important based upon previous animal studies with agr knockout
mutants that show a diminished capacity to initiate and persist in
a skin infection model. In the proposed study, we seek to improve
our understanding of the mechanistic basis for Extract 134's
quorum-quenching effects and evaluate the therapeutic relevance of
such an anti-virulence therapy using in vivo models. The study
will address four specific aims: 1) identification and structural
elucidation of the active constituent(s) (or marker compounds for
standardization) in Extract 134;2) elucidation of the mechanism of
action for the quorum-quenching effects observed;3) determination
of drug metabolism and pharmacokinetic parameters (DM/PK) of the
bioactive constituent(s);and 4) evaluation of efficacy in treating
S. aureus skin infection in a murine model.
PLoS ONE 11(9):e0163655 (September 2016 )
DOI: 10.1371/journal.pone.0163655
Correction: Castanea sativa (European
Chestnut) Leaf Extracts Rich in Ursene and Oleanene
Derivative...
Hospital superbug MRSA could be beaten with
an unusual cure
Researchers used a Mediterranean folk remedy to obtain an
extract that stopped staphylococcus aureus producing harmful
toxins in mice
By John von Radowitz
Chemicals from sweet chestnut tree leaves can help fight the MRSA
superbug, scientists have found.
They used a Mediterranean folk remedy to obtain an extract that
stopped staphylococcus aureus producing harmful toxins in mice.
Cassandra Quave of Emory University, Atlanta, Georgia, said it did
not kill the bug but “takes the teeth out of the bacteria’s bite”.
The compounds "disarm" Staphylococcus aureus bacteria and stop
them producing harmful toxins.
Yet they do not appear to boost levels of drug resistance.
Dr Quave said: "Rather than killing staph, this botanical extract
works by taking away staph's weapons, essentially shutting off the
ability of the bacteria to create toxins that cause tissue
damage."
For years the Emory team had investigated the traditional remedies
of rural people in southern Italy and other parts of the
Mediterranean.
Detective work by the researchers led them to the European sweet
chestnut tree, Castanea sativa.
"Local people and healers repeatedly told us how they would make a
tea from the leaves of the chestnut tree and wash their skin with
it to treat skin infections and inflammations," said Dr Quave.
In the laboratory, the scientists steeped chestnut leaves in
solvents to extract 94 chemicals including the anti-bacterial
ursene and oleanene compounds.
A single 50 microgram dose of the extract cleared up MRSA skin
infections in laboratory mice, halting damage to tissue and red
blood cells.
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0136486
PLOS ONE, 2015; 10 (8): e0136486
DOI: 10.1371/journal.pone.0136486
Castanea sativa (European Chestnut) Leaf
Extracts Rich in Ursene and Oleanene Derivatives Block
Staphylococcus aureus Virulence and Pathogenesis without
Detectable Resistance.
Cassandra L. Quave, James T. Lyles, Jeffery S. Kavanaugh,
Kate Nelson, Corey P. Parlet, Heidi A. Crosby, Kristopher P.
Heilmann, Alexander R. Horswill.
Abstract
The Mediterranean is home to a rich history of medical traditions
that have developed under the influence of diverse cultures over
millennia. Today, many such traditions are still alive in the folk
medical practices of local people. Investigation of botanical folk
medicines used in the treatment of skin and soft tissue infections
led us to study Castanea sativa (European Chestnut) for its
potential antibacterial activity. Here, we report the quorum
sensing inhibitory activity of refined and chemically
characterized European Chestnut leaf extracts, rich in oleanene
and ursene derivatives (pentacyclic triterpenes), against all
Staphylococcus aureus accessory gene regulator (agr) alleles. We
present layers of evidence of agr blocking activity (IC50 1.56–25
µg mL-1), as measured in toxin outputs, reporter assays hemolytic
activity, cytotoxicity studies, and an in vivo abscess model. We
demonstrate the extract’s lack of cytotoxicity to human
keratinocytes and murine skin, as well as lack of growth
inhibitory activity against S. aureus and a panel of skin
commensals. Lastly, we demonstrate that serial passaging of the
extract does not result in acquisition of resistance to the quorum
quenching composition. In conclusion, through disruption of quorum
sensing in the absence of growth inhibition, this study provides
insight into the role that non-biocide inhibitors of virulence may
play in future antibiotic therapies.
A series of studies by Quave et al. [4–6] investigated the
bioactivity of plant extracts used in the traditional treatment of
skin and soft tissue infections (SSTI) in Italy. Extracts were
screened for activity against multiple targets, including S.
aureus biofilms, communication (quorum-sensing) and growth. As a
result of this work, three potential leads (Castanea sativa,
Ballota nigra, and Sambucus ebulus) for the inhibition of quorum
sensing in the absence of growth-inhibitory effects were
identified [4]. Here, we continue to explore other mechanisms by
which anti-infective traditional botanical medicines may function,
and report the discovery of quorum quenching natural products
extracted from Castanea sativa (European Chestnut) leaves, which
are used in traditional therapies for treating skin inflammation
SSTIs in the Mediterranean [7]. Notably, we report the ability of
C. sativa leaf extracts to attenuate virulence by quenching S.
aureus agr-mediated quorum sensing, effectively blocking
production of harmful exotoxins at sub-inhibitory concentrations
for growth. We also report the lack of cytotoxicity to human skin
cells, lack of growth inhibitory activity against the normal skin
microflora, lack of resistance development, and efficacy in a skin
abscess animal model...
Extraction and purification of QSI-containing fractions
Crude methanol extracts (Extract 224) of the ground leaves were
created by maceration of the plant materials at room temperature
using a ratio of 1g dry leaves:10 mL MeOH for two successive
periods of 72 hours, with daily agitation. Filtered extracts were
combined, concentrated at reduced pressure and a temperature
<40°C with rotary evaporators, and lyophilized before being
re-suspended in water and partitioned in succession with hexane,
ethyl acetate and butanol (all solvents acquired from Fisher
Chemical, Certified ACS). The resulting non-aqueous partitions
were dried over anhydrous Na2SO4, concentrated in vacuo, and
lyophilized before testing for activity.
The most active partition (ethyl acetate, extract 224C) was
subjected to further fractionation using a CombiFlash Rf+
(Teledyne ISCO) flash chromatography system using a RediSep Rf
Gold silica column. Extract 224C was bonded to Celite 545 (Acros
Organics) at a 1:4 ratio and dry-loaded using a RediSep dry load
cartridge. The mobile phase consisted of (A) hexane, (B) EtOAc,
and (C) MeOH. The linear gradient begins with 100% A for 6.3
column volumes (CV), and then increased to 50:50 A:B by25.3 CV,
and increased to 100% B at 63.3 CV, which was held until 69.6 CV,
and then to 70:30 B:C at 88.6 CV, which was held until 94.9 CV.
The chromatography was monitored at 254 and 280 nm, as well as via
ELSD. The resulting fractions were combined into 5 fractions.
Following further bioassay testing, it was determined that the
fraction which eluted from 30–40 CV (224C-F2) was most active. The
full extract fractionation scheme is presented in Fig 2...
Discussion
The ethnobotanical approach to drug discovery [55] was used here
to identify Castanea sativa leaves as a potential source new
anti-infective agents. Through design of a bioactivity-guided
fractionation strategy based on limited growth-impact coupled to
quorum sensing inhibition, we were successful in creating a highly
efficacious botanical composition with universal quenching
activity for all agr alleles. To the best of our knowledge, the
present work represents the first in-depth investigation of
European Chestnut leaf extract for its quorum quenching and
anti-virulence effects since its identification as a potential
quorum quenching lead [4]. Furthermore, this is the first report
of the quorum quenching effects of a botanical composition rich in
ursene and oleanene derivatives (Fig 10) against S. aureus.
Additional compounds identified in the most active region (at
<1% relative abundance each) included putative gallotannins,
which share a tri-galloyl structure with varying core sugars (32,
33, 34), and a putative ellagitannin (39). It is possible that in
addition to the pentacyclic triterpenes present in 224C-F2,
hydrolysable tannins also contribute to the extract’s quorum
quenching activity.
European Chestnut leaf extracts have been the focus of a number of
studies centered on evaluation of its activity in scavenging
reactive oxygen species [42, 56] and cytoprotective effects,
specifically with regards to protection from UV-damage in skin
cells [57]. The examination of European Chestnut leaf extracts
with a patch test revealed that with respect to irritant effects,
such extracts can be considered as safe for topical applications
[58]. The integration of C. sativa leaf extracts into cosmetic
compositions has also been patented, and is based on the
antibacterial and reactive oxygen species (ROS) scavenging effects
of the extract [59]. Our safety studies in both human keratocytes
(HaCaT cells) and murine skin (Fig 6) have reconfirmed that this
version of European Chestnut leaf extract (224C-F2) can be
considered safe for topical applications based on its lack of
cytotoxic and irritant effects.
Several layers of evidence in support of the efficacy of C. sativa
leaf extracts in blocking S. aureus virulence have been presented.
Specifically, we have demonstrated that European Chestnut leaf
extracts are effective in blocking production of the translational
products of RNAIII, including a number of exotoxins. Overall
virulence was quenched as demonstrated by the lack of cytotoxic
effects elicited by supernatants of cultures treated with the
extract. Importantly, using an in vivo model, we have demonstrated
efficacy in attenuating dermonecrosis, even in the absence of
adjuvant antibiotics.
This inhibition of virulence and pathogenesis was accomplished
without posing growth inhibitory pressures on not only S. aureus,
but also a panel of common members of the human cutaneous
microbiome. A robust skin microflora is critical to skin barrier
health and prevention of disease onset. The majority of the
bacterial cutaneous microbiome is represented by Actinobacteria,
Firmicutes, Proteobacteria and Bacteroidetes [60]. Much like cases
of dysbiosis in gut microflora, broad-spectrum activity against
the skin microflora also holds the potential for fostering an
environment amenable to the proliferation of pathogenic bacteria
[61]. The presence of commensals, like Staphylococcus epidermidis,
is essential to state of host innate immunity [62]. Thus, it is
noteworthy that 224C-F2 specifically blocks S. aureus virulence
without adding selective pressures on major representatives of the
cutaneous microbiome.
The mechanistic basis for 224C-F2’s quorum quenching activity
remain unclear. Multiple lines of evidence suggest that components
within 224C-F2 directly target the core machinery of the agr
system, such as our observation of agr P3 promoter reduction (Fig
3) and reduced levels of d-toxin production (Fig 4), which is
encoded within RNAIII transcript regulated by P3. If 224C-F2 only
targeted downstream factors regulated by quorum sensing, such as
a-hemolysin, inhibition of agr P3 or d-toxin production would not
have been expected. Potential targets within the agr system
include inhibition of AIP docking with AgrC, prevention of AIP
production through AgrB, or reduction of AgrA activation (Fig 1).
Future studies will seek to resolve the mechanism, and this will
be facilitated by the isolation of individual active components
for incorporation in structure-activity relationship (SAR)
studies.
We hypothesized that use of a complex mixture that targets an
indirect pathway to pathogen success (rather than direct targeting
for growth and survival) would be unlikely to result the
generation of resistant mutations. In fact, following 15 days of
sequential passaging with 224C-F2 in vitro, no resistance was
detected. This is not surprising; recent findings comparing
individual natural products to complex botanical compositions in
other targets, such as multidrug-resistant malaria, have
demonstrated that single-compound drugs may not be the best
answer. For example, in the face of growing artemisinin resistance
for malaria, more chemically complex whole plant therapies
(Artemisia annua L., Asteraceae) have demonstrated superior
efficacy to the single compound in preventing drug resistance
[63]. Indeed, complex botanical compositions that meet the FDA
standards for safety and efficacy are eligible for an alternative
regulatory approval pathway as “botanical drugs”, which are
distinct from dietary supplements, and are standardized to levels
of marker compounds and regulated like other single compound
pharmaceuticals once approved [64]. Two examples of successful
botanical drugs include Veregen (Camellia sinensis (L.) Kuntze,
Theaceae, sinecatechin topical formulation for anogenital warts)
and Fulyzaq (Croton lechleri Müll. Arg., Euphorbiaceae,
procyanidin and prodelphinidin oral formulation for
HIV/AIDS-related diarrhea).
While it is debatable whether virulence inhibitors will ever serve
as stand-alone therapeutics, many agree that their application as
adjuvants to existing lines of antibiotics could be a critical
tool in this era of rising antibiotic resistance. Specifically, by
inhibiting agr, such a therapy effectively blocks the production
of an entire suite of diverse staphylococcal toxins, ranging from
immune-attacking PSMs, pore-forming hemolysins, and a number of
other proteases and lipases that damage the host tissue and weaken
the host immune response. This will be of particular relevance to
patients faced with toxin-mediated infection, including
staphylococcal scalded skin syndrome (esp. in neonates),
abscesses, necrotizing fasciitis, sepsis, atopic dermatitis
(eczema) and more.
In conclusion, we have demonstrated that a folk-medical treatment
for skin inflammation and SSTIs that does not demonstrate
“typical” antibacterial activity (bacteriostatic or bactericidal)
nevertheless shows great potential for development as a
therapeutic due to its ability to specifically target and quench
S. aureus virulence. The results of this study are important not
only to future antibiotic discovery and development efforts, but
are also vital to the validation of this previously poorly
understood traditional medicine as an efficacious therapy, and not
simply an unsubstantiated relict of folklore. Importantly, this
composition was non-toxic to human keratinocytes and no
dermatopathology was noted upon administration to murine skin.
Moreover, the composition did not inhibit growth of the normal
skin microflora, suggesting that its disruptive action on the
cutaneous microbiome would be minimal to nil. Future work will
focus on evaluation of individual actives within the composition
with the aim of determining whether a complex mixture, such as
224C-F2 or a single compound will prove most effective against all
agr alleles and which will be least likely to develop resistance
when administered under multiple selective pressures, such as for
in vivo administration as an antibiotic adjuvant...
[ Excerpts ]
Botanical Extracts and
Compounds from Schinus Plants and Methods of Use
US2017007652
This disclosure relates to extracts from the Anacardiaceae (cashew
plant family) and compositions comprising compounds contained
therein. In certain embodiments, the extracts are derived from the
fruit of a Schinus plant. In certain embodiments, the disclosure
relates to methods of treating or preventing bacterial infections,
acne, and other related uses.
BACKGROUND
[0003] Since the widespread introduction of antibiotics in the
1940s, the same storyline has repeated itself over and over again:
new antibiotic is introduced and then resistant variants emerge
and quickly spread, effectively limiting the utility and lifespan
of the drug. Staphylococci are frequently the cause of hospital
infections such as infections from implanted medical devices. Many
staphylococcal strains have become resistant to many modern day
antibiotics. Improved therapies are needed.
[0004] One proposed strategy to overcome the problem of highly
virulent and resistant variants is to indirectly attack bacteria
by interfering with their means of communication, also known as
quorum sensing. Targeting microbial communication makes sense
because bacteria coordinate many of their virulence and
pathogenesis pathways through these systems. Quave et al., report
quorum sensing inhibitors of Staphylococcus aureus from botanical
extracts. Planta Med. 2011, 77(02):188-95. See also Quave &
Horswill, Front Microbiol, 2014, 5:706.
[0005] Schinus terebinthifolia Raddi (synonym: Schinus
terebinthfolius) is a flowering plant in the family Anacardiaceae,
which can be found in Brazil, the Caribbean and across the
southern United States. It is considered an invasive species in a
number of countries. El-Massry et al. report chemical compositions
and antioxidant/antimicrobial activities of various samples
prepared from Schinus terebinthifolia leaves cultivated in Egypt.
J Agric Food Chem, 2009, 57:5265-5270. Moura-Costa et al. report
antimicrobial activity of plants used as medicinals on an
indigenous reserve in Rio das Cobras, Parana, Brazil. J
Ethnopharmacol, 2012, 143:631-638. Melo et al. report alcohol
extract of Schinu sterebinthifolia Raddi (Aanacardiaceae) as a
local antimicrobial agent in severe autogenously fecal peritonitis
in rats. Acta cirurgica brasileira/Sociedade Brasileira para
Desenvolvimento Pesquisa em Cirurgia, 2014, 29 Suppl 1:52-56. See
also Martius, Systema de Materia Medica Vegetal Brasileira. Rio de
Janeiro, 1854; Moreira, Diccionario de Plantas Medicinaes
Brasileiras. Rio de Janeiro, 1862; Chernoviz, Formulario ou Guia
Medica. 6 ed. Paris, 1864; Burton, Viagens aos planaltos do
Brasil—Tomo I: Do Rio de Janeiro a Morro Velho, 1868
SUMMARY
[0007] This disclosure relates to extracts from the cashew family
of plants (Anacardiaceae) and compositions comprising one or more
compounds contained therein and related uses reported herein. In
certain embodiments, the extracts are derived from the fruit of a
Schinus plant such as Schinus terebinthifolia.
[0008] In certain embodiments, the disclosure relates to extracts
comprising a fruit derived mixture of compounds from a Schinus
plant wherein the extracting process comprises one or more of the
following steps of: mixing a fruit with an alcohol, e.g., ethanol,
methanol, or aqueous mixtures thereof (ethanol:water or
methanol:water, 50-95% alcohol, 80% methanol) under conditions
such that fruit compounds dissolves in the methanol and removing
the methanol providing a methanol derived mixture of compounds;
partitioning the methanol derived mixture of compounds between
hexane and water providing a water derived mixture of compounds;
partitioning the water derived mixture of compounds between ethyl
acetate and water providing a second water derived mixture of
compounds; partitioning the second water derived mixture of
compounds by mixing the second water derived mixture of compounds
with n-butanol under conditions such that fruit compounds dissolve
in the n-butanol and removing the n-butanol providing an n-butanol
derived mixture of compounds; and purifying the n-butanol derived
mixture of compounds by liquid chromatography.
[0009] In certain embodiments, the extract comprises a mixture of
compounds having at least one component from each of the following
groups a) to d): a) a compound having a molecular formula of
C30H17O10; b) a compound having a molecular formula of C30H21O10;
c) a compound having a molecular formula of C30H45O4; and d) a
compound having a molecular formula of C30H45O4.
[0010] In certain embodiments, this disclosure relates to methods
of treating or preventing bacterial infections or acne comprising
administering to a subject in need thereof or contacting the skin
of a subject in need thereof with a formula comprising an extract
or one or more compounds in an extract as disclosed herein. In
certain embodiments, the formula is administered in combination
with another antibiotic.
[0011] In certain embodiments, this disclosure relates to methods
of treating or preventing a toxin-mediated bacterial infection
comprising administering an effective amount of an Schinus extract
or compounds contained therein to a subject in need thereof,
including a subject at risk of, exhibiting symptoms of, or
diagnosed with a staphylococcal scalded skin syndrome (esp. in
neonates), abscesses, necrotizing fasciitis, sepsis, or atopic
dermatitis (eczema).
[0012] In certain embodiments, the subject is at risk of,
exhibiting symptoms of, or diagnosed with toxic shock syndrome,
scalded skin syndrome, abscesses, furuncles, cellulitis,
folliculitis, bloodstream infections, medical device infections,
pneumonia, osteomyelitis, staphylococcal food poisoning, skin and
soft tissue infections, endocarditis, eczema, atopic dermatitis,
psoriasis, impetigo, septic arthritis, brain abscess, burn wounds,
venous ulcers, diabetic foot ulcers, surgical wounds,
post-operation infections, carbuncles, meningitis, bacteremia,
necrotizing pneumonia, or necrotizing fasciitis...
Extracts and Compounds
[0072] In certain embodiments, an extract is made by the process
of extracting a mixture of compounds from the leaves, roots, bark,
stem, fruit, or branches of a Schinus plant such as Schinus
terebinthifolia. Other contemplated plants include: Schinus andina
and varieties (andina and subtridentata), Schinus angustifolia,
Schinus antiarthritica, Schinus areira, Schinus bituminosa,
Schinus bonplandiana, Schinus brasiliensis, Schinus bumelioides,
Schinus canrerae, Schinus chebataroffi, Schinus chichita, Schinus
crenata, Schinus dentata, Schinus dependens and varieties (alfa,
arenicola, brevifolia, crenata, grandifolia, longifolia, obovata,
ovata, paraguarensis, parvifolia, patagonica, subintegra,
tomentosa), Schinus discolor, Schinus diversifolia, Schinus
engleri and varieties (engleri, uruguayensis), Schinus fagara,
Schinus fasciculate and varieties (arenaria, arenicola,
boliviensis, fasciculata), Schinus ferox, Schinus gracilipes and
varieties (gracilipies, pilosus), Schinus huigan, Schinus huyngan
and varieties (heterophyllus, longifolius, obovatus,
subtridentata, undulate), Schinus indicus, Schinus johnstonii,
Schinus latifolius and varieties (tomentosus), Schinus
lentiscifolius and varieties (angustifolia, flexuosa, subobtusa),
Schinus leucocarpus, Schinus limonia, Schinus longifolia and
varieties (longifolia, paraguarensis), Schinus marchandii, Schinus
maurioides, Schinus mellisii, Schinus meyeri, Schinus microphylla,
Schinus microphyllus, Schinus molle and varieties (areira,
argentifolius, hassleri, huigan, huyngan, molle, rusbyi), Schinus
molleoides, Schinus montanus and varieties (crenuloides,
patagonicus), Schinus mucronulatus, Schinus myricoides, Schinus
myrtifolia, Schinus occidentalis, Schinus odonellii, Schinus
paraguarensis, Schinus patagonicus and varieties (crenuloides,
patagonicus), Schinus pearcei, Schinus pilifera and varieties
(boliviensis, cabrerae, pilifer), Schinus polygama and varieties
(australis, chubutensis, crenata, fasciculata, heterophylla,
ovata, parviflora, patagonica), Schinus polygamus, Schinus
praecox, Schinus pubescens, Schinus ramboi, Schinus resinosus,
Schinus rhoifolia, Schinus roigii, Schinus sinuatus, Schinus
spinosus, Schinus tenuifolius, Schinus terebinthifolius and
varieties (acutifolia, damaziana, glaziovana, pohlianus, raddiana,
rhoifolia, selloana, terebinthifolia, ternifolia), Schinus
terebinthifolius, Schinus ternifolia, Schinus tomentosa, Schinus
tragodes, Schinus velutinus, Schinus venturii, Schinus
weinmannifolius and varieties (angustifolius, dubius, glabrescens,
hassleri, intermedius, pauciflorus, paucijuga, pubescens,
riedelianus, ridelianus, weinmannifolius) and hybrids thereof.
[0073] In certain embodiments, the extracting process comprises
the step of mixing the fruit from the plant with a polar solvent,
such as a liquid comprising methanol, ethanol, ethyl acetate,
n-butanol, acetonitrile, acetone, methylene chloride or
chloroform, under conditions such that a mixture of compounds in
the fruit dissolves in the solvent. In certain embodiments, the
process further comprises the step of removing the solvent by
evaporation from the mixture of compounds. In certain embodiments,
the process further comprises the step of purifying the mixture of
compounds by liquid chromatography through a solid absorbent,
e.g., wherein the solid absorbent comprises silica gel or
alumina...
[0078] In certain embodiments, methods of extraction comprise
mixing the fruit of a Schinus plant with an water miscible carbon
containing solvent, e.g., such as a protic solvent, an alcohol,
methanol, ethanol, 1-propanol, 2-propanol, tetrahydrofuran,
acetone, acetic acid, 1,4-dioxane or mixture providing a
concentrate with a mixture of compounds and substantially removing
the solvent from the concentrate, purifying the solvent derived
concentrate to less than 5%, 1%, or 0.5% by weight of the solvent
used in the extraction, e.g., evaporating the protic solvent
and/or optionally in combination with mixing the concentrate with
water, sonicating the water, freezing the water to provide ice,
and removing the ice by sublimation (e.g. in a vacuum of low
pressure) wherein said purification methods may be repeated in
combination. In certain embodiments, the method further comprises
suspending the solvent derived concentrate in water and optionally
extract impurities in a hydrocarbon solvent such as cyclohexane,
heptane, hexane, pentane, 2,2,4-trimethylpentane, separating the
hydrocarbon from the water providing a water layer. In certain
embodiments, the method further comprises mixing the water layer
with a solvent that is immiscible in water (polar and/or aprotic),
e.g., such as ethyl acetate, diethyl ether, methyl tertbutyl
ether, n-butanol, toluene, methylene chloride, carbon
tetrachloride, 1,2-dichloroethant, and/or chloroform, and
purifying the solvent to provide a second solvent derived
concentrate. In further embodiments, the second derived
concentrate is purified one or more times by liquid
chromatography, e.g., normal phase chromatography...
EXAMPLES
Collection of Plant Material
[0161] Schinus terebinthifolia Raddi, Anacardiaceae leaves, stems,
and fruits were collected in bulk from private lands in DeSoto
County, Fla. in November of 2013 and 2014 after obtaining
permission from the land owner. Procedures from the 2003 WHO
Guidelines for good agricultural and collection practices (GACP)
for medicinal plants were followed for the collection and
identification of bulk and voucher specimens, specifically
excluding any populations that may have prior exposure to
herbicides. Vouchers were deposited at the Emory University
Herbarium (GEO) (Voucher CQ-400, GEO Accession No. 020063) and
were identified using the standard Flora for Florida. Plant
leaves, stems, and fruits were separated and manually cleaned of
soil and contaminants. Plant material was then dried in a
desiccating cabinet at low heat. Once dry, plant material was
sealed in paper bags and stored at room temperature until further
processing.
Extraction and Separation.
[0162] Crude methanol extracts of fruits were created by blending
a ratio of 1 g dry material:10 mL MeOH into a slurry in a Waring
commercial blender for 5 min, and sonicating the material for 20
minutes. Following decantation of the extract, plant material was
subjected to two more rounds of sonication followed by filtration.
Filtered extracts were combined, concentrated at reduced pressure
with rotary evaporators (<40° C.), and lyophilized. The dried
extract was resuspended in 1:5 MeOH:H2O at 1 g:31 mL and underwent
sequential liquid-liquid partitioning three times each with an
equal volume of hexane, EtOAc, and H2O saturated n-butanol. The
organic partitions were dried over Na2SO4 and filtered. Each
partition was concentrated in vacuo at <40° C. The hexane
partition was dissolved and transferred to a tared scintillation
vial and dried under forced air to yield 430B. The remaining
partitions were suspended in dH2O, shell frozen, lyophilized and
stored at −20° C. The EtOAc partition was labeled 430C, the
n-butanol 430D, and final remaining aqueous partition 430E...
[ Excerpts ]
Botanical Extracts and Compounds from
Castanea Plants and Methods of Use
US2016375074
This disclosure relates to extracts from chestnut plants and
compositions comprising compounds contained therein. In certain
embodiments, the extracts are derived from the leaves of a
Castanea plant. In certain embodiments, the disclosure relates to
methods of treating or preventing bacterial infections, acne, and
other related uses...
BACKGROUND
[0003] Since the widespread introduction of antibiotics in the
1940s, the same storyline has repeated itself over and over again:
new antibiotic is introduced and then resistant variants emerge
and quickly spread, effectively limiting the utility and lifespan
of the drug. From an evolutionary biology perspective, this is not
surprising; indeed, resistant mutants are expected to arise when
any lifeform with the ability to rapidly reproduce and mutate is
faced with a direct selective pressure, especially when a single
drug is used against a single target. Staphylococci are frequently
the cause of hospital infections such as infections from implanted
medical devices. Many Staphylococci strains have become resistant
to many modern day antibiotics. Improved therapies are needed.
[0004] One proposed strategy to overcome the problem of resistant
variants is to indirectly attack bacteria by interfering with
their means of communication, also known as quorum sensing.
Targeting microbial communication makes sense because bacteria
coordinate many of their virulence and pathogenesis pathways
through these systems. Quave et al., report quorum sensing
inhibitors of Staphylococcus aureus from botanical extracts.
Planta Med. 2011, 77(02):188-95.
[0005] Castanea sativa (chestnut) is a flowering plant in the
family Fagaceae which can be found in Europe. See Braga et al.,
Nat Prod Res., 2015, 29(1):1-18. Almeida et al. report in vivo
skin irritation potential of a Castanea sativa (Chestnut) leaf
extract. Basic & Clinical Pharmacol Toxicol, 2008,
103(5):461-7. See also Almeida et al. J Photochem Photobiol B:
Biol, 2015, 144(0):28-34. Henry et al. report cosmetic
compositions containing an extract of leaves of the Castanea
sativa plant and cosmetic treatments. U.S. Pat. No. 8,067,044
(2011).
[0006] Garo et al., report asiatic acid and corosolic acid enhance
the susceptibility of Pseudomonas aeruginosa biofilms to
tobramycin. Antimicrob Agents Chemother, 2007, 51(5):1813-7. See
also Rangasamy et al. South African J Botany, 2014, 93:198-203.
[0007] Wong et al. report aqueous methanolic extracts of Melastoma
malabathricum L. exhibited antibacterial activity. Nat Prod Res,
2012,26(7):609-18
[0008] Perioni et al. report a survey on the natural ingredients
used in folk cosmetics, cosmeceuticals and remedies for healing
skin diseases. J Ethnopharmacol, 2004, 91(2-3):331-44.
[0009] References cited herein are not an admission of prior art.
SUMMARY
[0010] This disclosure relates to extracts from chestnut plants
and compositions comprising one or more compounds contained
therein and related uses reported herein. In certain embodiments,
the extracts are derived from the leaves of a Castanea plant such
as Castanea sativa.
[0011] In certain embodiments, the disclosure relates to extracts
comprising a leaf derived mixture of compounds from a Castanea
plant wherein the extracting process comprises one or more of the
following steps of: mixing a leaf with methanol under conditions
such that leaf compounds dissolves in the methanol and removing
the methanol providing a methanol derived mixture of compounds;
partitioning the methanol derived mixture of compounds in hexane
and water providing a water derived mixture of compounds;
partitioning the water derived mixture of compounds by mixing the
water with ethyl acetate under conditions such that leaf compounds
dissolve in the ethyl acetate and removing the ethyl acetate
providing an ethyl acetate derived mixture of compounds; and
purifying the ethyl acetate derived mixture of compounds by liquid
chromatography through silica with a mobile phase comprising
hexane and ethyl acetate; wherein the mobile phase comprises
increasing amounts of ethyl acetate, and a mobile phase fraction
is isolated comprising a leaf derived mixture of compounds which
does not contain chlorogenic acid, ellagic acid, hyperoside,
isoquercitrin, or rutin.
[0012] In certain embodiments, this disclosure relates to methods
of treating or preventing a bacterial infections or acne
comprising administering to a subject in need thereof or
contacting the skin of a subject in need thereof with a formula
comprising an extract or one or more compounds in an extract as
disclosed herein. In certain embodiments, the formula is
administered in combination with another antibiotic...
Chestnut Leaf Extracts Block Staphylococcus aureus Virulence and
Pathogenesis
[0063] Quorum quenching activity has been discovered in the
natural products extracted from Castanea sativa leaves. The
extract is able to attenuate virulence by quenching S. aureus
agr-mediated quorum sensing, effectively blocking production of
harmful exotoxins at sub-inhibitory concentrations for growth.
Experiments indicate a lack of cytotoxicity to human skin cells,
lack of growth inhibitory activity against the normal skin
microflora, lack of resistance development, and efficacy in a skin
abscess animal model.
[0064] Staphylococcus aureus is an abundant, opportunistic
pathogen that is the causative agent of numerous infections. Due
to its prevalence as a leading cause of healthcare-associated
infection, and its highly multidrug resistant nature, S. aureus is
a serious threat. It colonizes the nasal passages of approximately
30% of the healthy adult population. S. aureus infections initiate
through trauma to the skin or mucosal layer and then progress
through an invasive or toxin-mediated process. The prevalence of
these infections has increased due to higher rates of
immunosuppressive conditions, greater use of surgical implants,
and dramatic increases in antibiotic resistance.
[0065] S. aureus produces an extensive array of enzymes,
hemolysins, and toxins that are important to its ability to spread
through tissues and cause disease. These virulence factors serve a
wide scope of purposes in the infection process, including
disruption of the epithelial barrier, inhibition of opsonization
by antibody and complement, neutrophil cytolysis, interference
with neutrophil chemotaxis, and inactivation of antimicrobial
peptides. The expression of all of these invasive factors is
controlled by cell-density quorum sensing using the autoinducing
peptide (AIP) molecule. Like other quorum-sensing signals, AIP
accumulates outside the cell until it reaches a critical
concentration and then binds to a surface receptor called AgrC,
initiating a regulatory cascade. Since AIP controls the expression
of accessory factors for S. aureus, this regulatory system has
been named the accessory gene regulator (agr), and the majority of
the proteins necessary for this quorum-sensing system to function
are encoded in the agr chromosomal locus. Applying inhibitors to
quench this communication system to attenuate pathogenicity and
virulence lies at the core of the quorum quenching approach...
Extracts and Compounds
[0086] In certain embodiments, an extract is made by the process
of extracting a mixture of compounds from the leaves, roots, bark,
stem, or branches of a Castanea plant e.g., Castanea sativa. Other
contemplated plants include: Castanea acuminatissima, Castanea
alabamensis, Castanea alnifolia, Castanea americana, Castanea
argentea, Castanea argyrophylla, Castanea arkansana, Castanea
armata, Castanea ashei, Castanea blaringhemii, Castanea bodinieri,
Castanea brevicuspis, Castanea bungeana, Castanea burbankii,
Castanea buruana, Castanea californica, Castanea Castanea,
Castanea castanicarpa, Castanea castenea var. pubinervis, Castanea
chincapin, Castanea chinensis, Castanea chrysophylla, Castanea
concinna, Castanea cooperta, Castanea costata, Castanea coudersii,
Castanea crenata, Castanea davidii, Castanea dentata, Castanea
diversifolia, Castanea dovaricata, Castanea duclouxii, Castanea
echidnocarpa, Castanea edonii, Castanea edwii, Castanea
endicottii, Castanea eonii, Castanea fagus, Castanea falconeri,
Castanea fargesii, Castanea fauriei, Castanea fleetii, Castanea
floridana, Castanea formosana, Castanea furfurella, Castanea
glomerata, Castanea henryi, Castanea henryi, Castanea hupehensis,
Castanea hystrix, Castanea, Castanea inermis, Castanea japonica,
Castanea javanica, Castanea kusakuri, Castanea lanceifolia,
Castanea latifolia, Castanea margaretta, Castanea martabanica,
Castanea microcarpa, Castanea mollissima, Castanea montana,
Castanea morrisii, Castanea nana, Castanea neglecta, Castanea
ozarkensis, Castanea paucispina, Castanea phansipanensis, Castanea
prolifera, Castanea pubinervis, Castanea pulchella, Castanea
pumila, Castanea purpurella, Castanea regia, Castanea rhamnifolia,
Castanea rockii, Castanea roxburghii, Castanea seguinii, Castanea
sempervirens, Castanea sessilifolia, Castanea sinensis, Castanea
sloanea, Castanea spectabilis, Castanea sphaeroarpa, Castanea
sphaerocarpa, Castanea stricta, Castanea sumatrana, Castanea
tribuloides, Castanea tungurrut, Castanea vesca, Castanea
vilmoriniana, Castanea vulgaris, Castanea wattii and hybrids
thereof.
[0087] In certain embodiments, the extracting process comprises
the step of mixing the leaf from the plant with a polar solvent,
such as a liquid comprising methanol, ethanol, ethyl acetate,
acetonitrile, acetone, methylene chloride or chloroform, under
conditions such that a mixture of compounds in the leaf dissolves
in the solvent. In certain embodiments, the process further
comprises the step of removing the solvent by evaporation from the
mixture of compounds. In certain embodiments, the process further
comprises the step of purifying the mixture of compounds by liquid
chromatography through a solid absorbent, e.g., wherein the solid
absorbent comprises silica gel or alumina.
[0088] In certain embodiments, the disclosure relates to extracts
comprising a leaf derived mixture of compounds from a Castanea
plant wherein the extracting process comprises the steps of:
mixing a leaf with methanol under conditions such that leaf
compounds dissolves in the methanol and removing the methanol
providing a methanol derived mixture of compounds; partitioning
the methanol derived mixture of compounds in hexane and water
providing a water derived mixture of compounds; partitioning the
water derived mixture of compounds by mixing the water with ethyl
acetate under conditions such that leaf compounds dissolve in the
ethyl acetate and removing the ethyl acetate providing an ethyl
acetate derived mixture of compounds; and purifying the ethyl
acetate derived mixture of compounds by liquid chromatography
through silica with a mobile phase comprising hexane and ethylene
acetate; wherein the mobile phase comprises increasing amounts of
ethyl acetate, and a mobile phase fraction is isolated comprising
a leaf derived mixture of compounds which does not contain
chlorogenic acid, ellagic acid, hyperoside, isoquercitrin, or
rutin...
[0089] Chromatography refers to the separation of a mixture of
compounds dissolved in a fluid called the mobile phase, which
carries the compounds through a structure holding another material
called the stationary phase. The various compounds or components
of the mixture travel at different speeds, causing them to
separate. The separation is based on differential partitioning
between the mobile and stationary phases. Subtle differences in a
partition coefficient of each compound result in differential
retention on the stationary phase and thus changing the
separation.
[0090] In normal-phase chromatography, the stationary phase is
polar. In reversed phase, the stationary phase is nonpolar.
Typical stationary phases for normal-phase chromatography are
silica or organic moieties with cyano and amino functional groups.
For reversed phase, alkyl hydrocarbons are the preferred
stationary phase. Examples are solid supports containing a surface
conjugated with a hydrocarbon chain, e.g., octadecyl (C18), octyl
(C8), and butyl (C4).
[0091] In normal-phase chromatography, the least polar compounds
elute first and the most polar compounds elute last. The mobile
phase typically consists of a nonpolar solvent such as hexane or
heptane mixed with a slightly more polar solvent such as
isopropanol, ethyl acetate or chloroform. Retention to the
stationary phase decreases as the amount of polar solvent in the
mobile phase increases. In reversed phase chromatography, the most
polar compounds elute first with the most nonpolar compounds
eluting last. The mobile phase is generally a binary mixture of
water and a miscible polar organic solvent like methanol,
acetonitrile or THF.
[0092] In certain embodiments, methods of extraction comprise
mixing leaves of a Castanea plant with an water miscible carbon
containing solvent, e.g., such as a protic solvent, an alcohol,
methanol, ethanol, 1-propanol, 2-propanol, tetrahydrofuran,
acetone, acetic acid, 1,4-dioxane or mixture providing a
concentrate with a mixture of compounds and substantially removing
the solvent from the concentrate, purifying the solvent derived
concentrate to less than 5%, 1%, or 0.5% by weight of the solvent
used in the extraction, e.g., evaporating the protic solvent
and/or optionally in combination with mixing the concentrate with
water, sonicating the water, freezing the water to provide ice,
and removing the ice by sublimation (e.g. in a vacuum of low
pressure) wherein said purification methods may be repeated in
combination. In certain embodiments, the method further comprises
suspending the solvent derived concentrate in water and optionally
extract impurities in a hydrocarbon solvent such as cyclohexane,
heptane, hexane, pentane, 2,2,4-trimethylpentane, separating the
hydrocarbon from the water providing a water layer. In certain
embodiments, the method further comprises mixing the water layer
with a solvent that is immiscible in water (polar and/or aprotic),
e.g., such as ethyl acetate, diethyl ether, methyl tertbutyl
ether, toluene, methylene chloride, carbon tetrachloride, 1,2-di
chl oroethant, and/or chloroform, and purifying the solvent to
provide a second solvent derived concentrate. In further
embodiments, the second derived concentrate is purified one or
more times by liquid chromatography, e.g., normal phase
chromatography. Typically the solid absorbent is polar such as
silica. In certain embodiments, the extract is a portion isolated
after the column solvent is more than 50% ethyl acetate in
hexane...
Extraction and Purification of QSI-containing Fractions
[0181] Crude methanol extracts (Extract 224) of the ground leaves
were created by maceration of the plant materials at room
temperature using a ratio of 1 g dry leaves: 10 mL MeOH for two
successive periods of 72 hours, with daily agitation. Filtered
extracts were combined, concentrated at reduced pressure and a
temperature<40° C. with rotary evaporators, and lyophilized
before being re-suspended in water and partitioned in succession
with hexane, ethyl acetate and butanol. The resulting non-aqueous
partitions were dried over anhydrous Na2SO4, concentrated in
vacuo, and lyophilized before testing for activity.
[0182] The most active partition (ethyl acetate, extract 224C) was
subjected to further fractionation using a CombiFlash® Rf+
(Teledyne ISCO) flash chromatography system using a RediSep Rf
Gold silica column. Extract 224C was bonded to Celite 545 (Acros
Organics) at a 1:4 ratio and dry-loaded using a RediSep dry load
cartridge. The mobile phase consisted of (A) hexane, (B) EtOAc,
and (C) MeOH. The linear gradient begins with 100% A for 6.3
column volumes (CV), then 50:50 A:B at 25.3 CV, to 100% B at 63.3
CV, which is held till 69.6 CV, then to 70:30 B:C at 88.6 CV which
is held till 94.9 CV. The chromatography was monitored at 254 and
280 nm, as well as via ELSD. The resulting fractions were combined
into 5 fractions. Following further bioassay testing, it was
determined that the fraction which eluted from 30-40 CV (224C-F2)
was most active. The full extract fractionation scheme is
presented in FIG. 2...
[ Excerpts ]
ANTI-BIOFILM COMPOSITIONS AND METHODS FOR
USING
US2012088671
FIELD OF THE INVENTION
[0002] The present invention generally relates to biofilms. In
particular, it relates to compositions and methods for inhibiting
biofilm formation and/or reducing the growth of an established
biofilm.
BACKGROUND OF THE INVENTION
[0003] Staphylococcus aureus is arguably the most problematic
pathogen faced by modern healthcare systems today, owing in large
part to the persistent emergence of antibiotic resistant strains.
This is perhaps most evident in the recent appearance of
methicillin-resistant strains even among isolates causing
community-acquired infection. Moreover, many of these strains,
most notably those of the USA300 clonal lineage, have the capacity
to cause serious, life-threatening infection even in otherwise
healthy individuals. This accounts in large part for the
observation that, in the United States alone in 2005, an estimated
94,360 patients suffered from invasive infection caused by
methicillin-resistant S. aureus (MRSA), with approximately 18,650
resulting in a fatal outcome.
[0004] The continued emergence of antibiotic-resistant strains has
created an urgent need for new antimicrobial agents. However, many
S. aureus infections are recalcitrant to antimicrobials even in
the absence of issues related to acquired resistance. A primary
contributing factor to this recalcitrance is formation of a
biofilm on both native tissues and indwelling medical devices.
This is due to the fact that the biofilm confers a degree of
intrinsic resistance that often necessitates surgical intervention
to debride infected tissues and/or remove infected devices. For
example, one study found that nearly half of patients with
implanted orthopedic devices admitted to a hospital with S. aureus
bacteremia had developed an implant-associated infection. Thus,
while there is an urgent need for new antibiotics, there is an
equally urgent need to develop therapeutic agents that could be
used to limit biofilm formation. While such agents would not
necessarily function as antibiotics in and of themselves, they
could be used as a prophylactic to limit biofilm formation (e.g.
coating for implanted devices, surgical lavage, or pre-operative
oral prophylaxis) or as a therapeutic to be used in conjunction
with more conventional antibiotics to treat an established
biofilm-associated infection.
SUMMARY OF THE INVENTION
[0005] Among the various aspects of the present disclosure is the
provision of a polyphenolic composition. The polyphenolic
composition is prepared by a process comprising (a) partitioning
an alcohol extract of a plant with a mixture of water and hexane
to form a first water partition and a hexane partition; (b)
partitioning the first water partition with a mixture of water and
ethyl acetate to form a second water partition and a ethyl acetate
partition; (c) partitioning the second water partition with a
mixture of water and butanol to form a third water partition and a
butanol partition; and (d) fractionating the butanol partition by
column chromatography with a mobile phase comprising a mixture of
methanol and dichloromethane, wherein the polyphenolic composition
is eluted by the mobile phase in which the volume ratio of
methanol to dichloromethane is about 40:60.
[0006] Another aspect of the disclosure provides a combination
comprising at least one phenolic phytochemical and at least one
antimicrobial agent.
[0007] Still another aspect of the disclosure encompasses a method
for inhibiting formation of a biofilm. The method comprises
contacting a plurality of free floating microorganisms with the
polyphenolic composition detailed above or a fraction thereof such
that formation of the biofilm is inhibited.
[0008] A further aspect of the disclosure provides a method for
inhibiting growth of an established biofilm. The method comprises
contacting the biofilm with at least one phenolic phytochemical
and at least one antimicrobial agent such that the biofilm has a
reduced number of microorganisms.
[0009] Other features and iterations of the invention are
described in more detail below...
DETAILED DESCRIPTION OF THE INVENTION
[0023] The present invention provides compositions and methods for
inhibiting the formation and growth of biofilms. In one aspect,
the disclosure provides a polyphenolic composition comprising
ellagic acid and ellagic acid derivatives. The phenolic
composition is derived from a plant extract by a process disclosed
herein. It has been discovered that the polyphenolic composition
inhibits biofilm formation and increases susceptibility of an
established biofilm to antimicrobial agents. Another aspect of the
disclosure provides a combination comprising at least one phenolic
phytochemical and at least one antimicrobial agent, wherein the
combination inhibits the growth of established biofilms.
Advantageously, the activity of the combination disclosed herein
is synergistic, i.e., its activity is more than the sum of the
activity of each individual component. Also provided herein are
methods for inhibiting the formation of a biofilm, as well as
methods inhibiting the growth of an established biofilm.
[0024] (I) Polyphenolic Composition
[0025] In one embodiment a polyphenolic composition is provided.
The polyphenolic composition is prepared by a process comprising
(a) partitioning an alcohol extract of a plant with a mixture of
water and hexane to form a first water partition and a hexane
partition; (b) partitioning the first water partition with a
mixture of water and ethyl acetate to form a second water
partition and a ethyl acetate partition; (c) partitioning the
second water partition with a mixture of water and butanol to form
a third water partition and a butanol partition; and (d)
fractionating the butanol partition by column chromatography with
a mobile phase comprising a mixture of methanol and
dichloromethane, wherein the polyphenolic composition is eluted by
the mobile phase in which the volume ratio of methanol to
dichloromethane is about 40:60.
[0026] The method comprises a series of steps such that a fraction
enriched with a polyphenolic composition may be isolated from an
alcohol extract of a plant.
(a) Alcohol Extract
[0028] The alcohol extract may be derived from a plant belonging
to a variety of plant families. Non-limiting examples of suitable
plant families include Rosaceae, Fagaceae, Salicaceae, Myrtaceae,
Vitaceae, Ericaceae, Combretaceae, Elaeocarpaceae, Lythraceae,
Symplocaceae, Hypoxidaceae, Amaranthaceae, Juncaceae,
Juglandaceae, Sapindaceae, Lamiaceae, Magnoliaceae, Gentianaceae,
Apocynaceae, Moringaceae, Apiaceae, Rutaceae, Aquafoliaceae,
Santalaceae, Cornaceae, Asteraceae, Bignoniaceae, and Fabaceae.
Preferred plant families include Rosaceae, Fagaceae, Salicaceae,
Myrtaceae, Vitaceae, Ericaceae, Combretaceae, and Juglandaceae. In
some embodiments, the plant may be Castanea sativa, Quercus
cerris, Juglans regia, Vitis vinefera, Crataegus monogyna, Prunus
spinosa, Rosa canina, or Rubus ulmifolius. In some embodiments,
the plant family may be Rosaceae. In an exemplary embodiment, the
plant may be Rubus ulmifolius.
[0029] A variety of plant parts may be used to arrive at the
alcohol extract. Suitable plant parts include roots, bulbs,
tubers, leaves, basal leaves, stems, stem nodes, stem internodes,
galls, stalks, woody parts, flowers, inflorescences, fruits,
infructescences, seeds, and combinations thereof. The plant part
may be fresh, dried, frozen, or lyophilized. The plant part may be
ground or pulverized into a plant material using a homogenizer, a
blender, a mortar and pestle, a sonicator, or a similar apparatus.
[0030] The plant extract typically is prepared by contacting the
plant material with an alcohol solvent for an appropriate period
of time. Non-limiting examples of suitable alcohol solvents
include methanol, ethanol, propanol, butanol, or combinations
thereof. In preferred embodiments, the solvent may be ethanol such
that the alcohol extract is an ethanol extract. The concentration
of alcohol that is contacted with the plant material may range
from about 1% to about 100%. In embodiments in which ethanol is
the solvent, the concentration of ethanol may range from about 1%
to about 20%, from about 20% to about 40%, from about 40% to about
60%, from about 60% to about 80%, or from about 80% to about 100%.
In an exemplary embodiment, the concentration of ethanol may be
about 95%.
[0031] The period of time the plant material is contacted with the
alcohol solvent may range from about 1 hour to about 5 days. In
various embodiments, the plant material may be contacted with the
alcohol solvent for about 1-24 hours, for about 24-48 hrs, for
about 48-72 hours, for about 72-96 hours, or for about 96-120
hours. In an exemplary embodiment, the period of time the plant
material is contacted with the alcohol solvent may be about 72
hours: Upon removal of the extract from the plant material, the
plant material may be extracted one or more additional times with
fresh alcohol solvent, essentially as detailed above.
[0032] The alcohol solvent may be removed from the plant alcohol
extract to form a dry plant alcohol extract. Those of skill in the
art are familiar with suitable techniques to remove the alcohol
solvent including, without limit, evaporation, distillation, and
lyophillization.
(b) Liquid Extractions
[0034] The process for preparing a fraction rich in the
polyphenolic compounds comprises subjecting the plant alcohol
extract to a series of liquid extractions such that the
polyphenolic compounds are partitioned into one of the phases and
the other compounds are partitioned into the other phase. In
general, the series of liquid extractions comprises contacting the
plant alcohol extract (or partition thereof) with a solvent
system, wherein the polarity of one or more of the solvents
changes during each successive series of extractions. Those of
skill in the art are familiar with liquid extraction protocols and
suitable solvent systems. Generally, the liquids are mixed by
gentle inversion at room temperature. After separation of the
phases, the phase containing the polyphenolic compounds thereof
may be extracted one or more times with the solvents of interest.
[0035] For example, the first step of the process may comprise a
liquid extraction during which the plant alcohol extract is
partitioned in a mixture of water and an alkane to form a first
water partition and an alkane partition. Typically, the
polyphenolic compounds are partitioned into the water phase upon
extraction with a mixture of water and alkane. The alkane
typically will comprise from five to ten carbons, and may be
linear or branched. Suitable alkanes include, without limit,
pentane, hexane, heptane, octane, and combinations thereof. An
exemplary alkane is hexane.
[0036] In the next step of the process, for example, the first
water partition may be extracted in a mixture of water and a
non-polar solvent to form a second water partition and a non-polar
solvent partition. Generally, the polyphenolic compounds are
partitioned into the water phase upon extraction with a mixture of
water and non-polar solvent. In various embodiments, the non-polar
solvent may be ethyl acetate, butyl acetate, chloroform, diethyl
ether, or combinations thereof. An exemplary non-polar solvent is
ethyl acetate.
[0037] The next and final extraction step, for example, may
comprise extracting the second water partition with a mixture of
water and an alcohol to form a third water partition and an
alcohol partition. Typically, the polyphenolic compounds are
partitioned into the alcohol phase upon extraction with a mixture
of water and alcohol. The alcohol may comprise from one to ten
carbons, and may be linear or branched. Non-limiting examples of
suitable alcohols include methanol, ethanol, propanol,
isopropanol, butanol, pentanol, hexanol, and heptanol. An
exemplary alcohol is butanol.
[0038] In a preferred embodiment, the first liquid-liquid
extraction comprises water and hexane, the second liquid-liquid
extraction comprises water and etliyl acetate, and the third
liquid-liquid extraction comprises water and butanol.
(c) Column Chromatography
[0040] The method may further comprise fractionating the
polyphenolic-rich fraction by column chromatography. Typically,
the column will comprise an inorganic stationary phase.
Non-limiting examples of suitable inorganic stationary phase
materials include silica-based materials, silica gel, magnetic
silica particles, glass powder, diatomaceous earth, zeolites,
aluminium oxides, silicon oxides, titanium oxides, zirconium
oxides, and hydroxyapatite. In an exemplary embodiment, the column
chromatography comprises a silica gel stationary phase.
[0041] The mobile phase may comprise a mixture of methanol and
dichloromethane. Those of skill in the art will appreciate that
other mobile phases may be used to separate the polyphenolic
composition from the other compounds. In embodiments in which the
mobile phase comprises methanol and dichloromethane, the
concentration of dichloromethane in the mobile phase typically
decreases during the fractionation while the concentration of
methanol in the mobile phase increases during the fractionation.
The phenolic-rich fraction generally elutes from the column with a
volume ratio of methanol to dichloromethane from about 30:70 to
about 70:30. For example, the volume ratio of methanol to
dichloromethane that elutes a phenolic-rich fraction may range
from about 30:70, 32.5:67.5. 35:65, 37.5:62.5, 40:60, 42.5:57.5,
45:55, 47.5:52.5, 50:50, 52.5:47.5, 55:45, 57.5:42.5, 60:40,
62.5:37.5, 65:35, 67.5:32.5, or 70:30. In preferred embodiments,
the polyphenolic-rich fraction may elute from the column at a
volume ratio of methanol to dichloromethane of about 40:60, 50:50,
or 60:40. In an exemplary embodiment, the polyphenolic-rich
fraction may elute from the column at a volume ratio of methanol
to dichloromethane of about 40:60. The polyphenolic-rich fraction
may be dried by removing the mobile phase solvents using standard
procedures...
Related Patents
CN105267752
Natural plant bacteriostatic agent and preparation method
thereof
Inventor(s): WANG ZHENYU +
A natural plant bacteriostatic agent and a preparation method
thereof are provided. The natural plant bacteriostatic agent
comprises following materials by weight: Flos Lonicerae 300-350
parts, Fructus Forsythiae 300-350 parts, Herba Pogostemonis
200-220 parts, Folium Mori 100-110 parts, mint 100-120 parts,
Folium Artemisiae Argyi 100-120 parts, Radix Arnebiae seu
Lithospermi 200-210 parts, Radix Glycyrrhizae 100-110 parts,
Rhizoma Phragmitis 100-110 parts, sodium benzoate 3-4 parts, and
flavoring orange essence 20-24 parts. The natural plant
bacteriostatic agent is prepared by: primary decocting, secondary
decocting, tertiary decocting, concentrating, alcohol
precipitation and separation, concentrating, and preparing. The
invention has the advantages that the natural plant bacteriostatic
agent is made from herbs, has improved bacteriostatic effect, has
little side effect on human body and is nonirritating to the skin;
the natural plant bacteriostatic agent is applicable to skin and
mouth to play a good role in inhibiting Staphylococcus aureus,
Escherichia coli and the like, is nonirritating to the skin and
mouth, and is free of drug resistance; compared with market
bacteriostatic agents, the natural plant bacteriostatic agent has
a wide range of action and is safer and nonirritating.
CN105267273
Natural skin-protecting wound disinfectant and preparation
method thereof
Inventor(s): LI QINGYUAN +
The invention relates to a skin-protecting wound disinfectant. The
skin-protecting wound disinfectant is prepared from 1%-5% of
chitosan oligosaccharide, 30%-40% of medical ethanol, 5%-20% of
sweet wormwood herb extracting solution, 5%-30% of moringa leaf
extracting solution, 0.5%-5% of moringa seed oil and the balance
deionized water. According to the skin-protecting wound
disinfectant, the chitosan oligosaccharide is dissolved in the
moringa leaf extracting solution and the sweet wormwood herb
extracting solution and resists bacteria by cooperating with sweet
wormwood herbs, moringa seeds and low-concentration ethanol, the
chitosan oligosaccharide does not settle in the low-concentration
ethanol, and the antibacterial effectiveness of the disinfectant
is guaranteed. Significant sterilization and disinfection effects
on pathogenic bacteria such as common staphylococcus,
streptococcus and escherichia coli, common cold viruses and the
like are achieved without adding antibiotics or other
chemosynthetic antibiotic constituents, and moringa leaves and
moringa seeds both have significant skin-protecting and
moisturizing effects. Therefore, by means of the skin-protecting
wound disinfectant, a moistening use feeling is achieved, a
protection effect on skins is achieved, the antibacterial and
skin-protecting effects are lastingly effective, toxic and side
effects to human bodies do not exist, and pollution to the
environment does not exist.
CN102600053
Chinese medicinal herb-inorganic antibacterial agent
composite sterilization hand sanitizer and preparation
Inventor(s): ZUNLI MO; HAO GOU; XIAOYING MA;
JINGXIAN HE; CHAO FENG +
The invention provides a Chinese medicinal herb-inorganic
antibacterial agent composite sterilization hand sanitizer,
belonging to the field of chemicals for daily use. According to
the Chinese medicinal herb-inorganic antibacterial agent composite
sterilization hand sanitizer provided by the invention,
extractives of Artemisia argyi leaf, Artemisia annua, Scutellaria
baicalensis, Punica granatumpericarp and Glycyrriza uralensis are
served as a composite Chinese medicinal herb antibacterial agent,
and nanometer silver oxide is served as the inorganic
antibacterial agent, as a result, the potent sterilization ability
of the nanometer silver oxide is combined with the long-term
sterilization effect of the Chinese medicinal herbs to form a
novel sterilization hand sanitizer with potent, long-term
sterilization and bacteriostasis functions.; According to the
bacteriostatic tests of Escherichia coli, staphylococcus aureus
and Bacillus subtilis, the Chinese medicinal herb-inorganic
antibacterial agent composite sterilization hand sanitizer is good
in performance of sterilization and bacteriostasis.
CN1217927
Preparing method and prescription for Chinese medicinal herbs
Nongerdan for otopyosis
Inventor(s): SUN SHUNXIAO
A medicine in the form of pill for treating pyogenic tympanitis is
prepared from websterite and multiple Chinese-medicinal materials
and features high curative effect. It has the suppression action
to staphylococcus aureus, proteus, colibacillus, Bacillus
anthracis...